Format

Send to

Choose Destination
Biomaterials. 2013 Nov;34(35):8909-17. doi: 10.1016/j.biomaterials.2013.07.099. Epub 2013 Aug 19.

Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer.

Author information

1
Department of Pathology and Genomic Medicine, Houston Methodist Hospital, 6565 Fannin St., Houston, TX 77030, USA.

Abstract

CD30 is highly expressed on Hodgkins lymphoma and anaplastic large cell lymphoma, making it an attractive target for therapy. We describe the generation of serum-stabilized ssDNA aptamers that bind CD30 via a hybrid SELEX methodology. The selected aptamer bound CD30 with high affinity and specificity. Further optimization of the aptamer led to a short, truncated variant with a 50-fold higher affinity than its longer counterpart. The multivalent aptamer was able to induce oligomerization of CD30 receptors and, in effect, activate downstream signaling, which led to apoptosis of ALCL cells. Immunotherapy using aptamer-based co-stimulation provides an alternative to antibodies, and has potential to transform cancer treatment.

KEYWORDS:

ALCL; CD30; Cancer immunotherapy; Lymphoma; cHL; ssDNA aptamer

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center